Metformin Targets Foxo1 to Control Glucose Homeostasis
Metformin is the first-line pharmacotherapy for type 2 diabetes mellitus (T2D). Metformin exerts its glucose-lowering effect primarily through decreasing hepatic glucose production (HGP). However, the precise molecular mechanisms of metformin remain unclear due to supra-pharmacological concentration...
Main Authors: | Xiaoqin Guo, Xiaopeng Li, Wanbao Yang, Wang Liao, James Zheng Shen, Weiqi Ai, Quan Pan, Yuxiang Sun, Kebin Zhang, Rui Zhang, Yuyang Qiu, Qian Dai, Hongting Zheng, Shaodong Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/11/6/873 |
Similar Items
-
Metformin Attenuates ROS via FOXO3 Activation in Immune Cells
by: Jelka Hartwig, et al.
Published: (2021-04-01) -
Metformin Alleviates Radiation-Induced Skin Fibrosis via the Downregulation of FOXO3
by: Jin-Mo Kim, et al.
Published: (2018-07-01) -
Combination of Solamargine and Metformin Strengthens IGFBP1 Gene Expression Through Inactivation of Stat3 and Reciprocal Interaction Between FOXO3a and SP1
by: Qing Tang, et al.
Published: (2017-10-01) -
(Metformin-κ2N,N′)(salicylato-κ2O,O′)copper(II) trihydrate
by: Sandra Julieta Gutiérrez Ojeda, et al.
Published: (2018-02-01) -
Nuclear localization marker of FOXO3a: can it be used to predict doxorubicin response?
by: Chun eGong, et al.
Published: (2013-06-01)